Related Experiment Video

Updated: May 26, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials

Fei Liu1, Xianguo Chen2, Ejun Peng3

  • 1Department of Urology, the Second Affiliated Hospital of Nanchang University, Nanchang, 330006, China. phiger81@163.com.

Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban
|December 17, 2011
PubMed

Insights

Vascular endothelial growth factor (VEGF) targeted therapies show improved progression-free survival for metastatic renal cell carcinoma (mRCC) compared to immunotherapy. While offering benefits, the risk-benefit ratio of these novel mRCC treatments requires further evaluation.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Immunotherapy has been a standard treatment for metastatic renal cell carcinoma (mRCC) for over two decades.
  • Anti-angiogenesis targeted therapy, specifically inhibiting the vascular endothelial growth factor (VEGF) pathway, has emerged as a promising strategy for mRCC.
  • Direct comparison of VEGF pathway-targeted therapy efficacy against established immunotherapy is crucial for optimizing mRCC treatment.

Purpose of the Study:

  • To evaluate the effectiveness of vascular endothelial growth factor (VEGF) pathway-targeted therapy in treating metastatic renal cell carcinoma (mRCC).
  • To compare the efficacy of VEGF inhibiting drugs (sorafenib, sunitinib, bevacizumab) with traditional immunotherapy (interferon) and placebo in mRCC patients.
  • To analyze progression-free survival (PFS), overall response rate (ORR), overall survival (OS), and toxic effects associated with these treatments.

Main Methods:

  • Systematic search of electronic databases for relevant randomized controlled trials (RCTs).
  • Inclusion criteria focused on RCTs comparing VEGF inhibiting drugs (sorafenib, sunitinib, bevacizumab) against interferon (IFN) or placebo for mRCC.
  • Meta-analysis of pooled data from 7 RCTs involving 3451 patients to assess treatment outcomes and safety profiles.

Main Results:

  • Anti-VEGF agents significantly improved progression-free survival (PFS) and demonstrated substantial clinical benefits for mRCC patients.
  • Sunitinib showed a higher overall response rate (ORR) compared to interferon (47% vs 12%).
  • Bevacizumab plus interferon improved PFS and ORR but increased the risk of serious toxic effects by 31% compared to interferon alone. Sorafenib and sunitinib extended overall survival (OS) compared to interferon.

Conclusions:

  • VEGF pathway-targeted therapies offer improved PFS and significant therapeutic benefits for mRCC compared to interferon therapy.
  • Specific agents like sunitinib demonstrate superior ORR, while combinations like bevacizumab plus interferon show enhanced PFS and ORR, albeit with increased toxicity.
  • The risk-to-benefit ratio of VEGF pathway-targeted therapies in mRCC warrants further comprehensive evaluation to guide clinical decision-making.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...